157 related articles for article (PubMed ID: 4037809)
1. [A clinical trial of a new mitomycin C derivative, KW-2083 (7-N-(p-hydroxyphenyl)-mitomycin C)].
Takahashi K; Yokoyama M; Takahashi H; Wakui A
Gan To Kagaku Ryoho; 1985 Sep; 12(9):1787-93. PubMed ID: 4037809
[TBL] [Abstract][Full Text] [Related]
2. [Phase II study of KW 2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with various cancers].
Nishi I; Yokoyama T; Nakao I; Harashima S; Ohashi Y; Kanko T; Saito T
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2513-9. PubMed ID: 6508315
[TBL] [Abstract][Full Text] [Related]
3. [Phase I-II study of 7-N-(P-hydroxyphenyl)-mitomycin C (KW2083, M83)].
Meguro S; Nagata T; Yokoyama K; Chinen T; Kobayashi T; Yamazaki H; Kuraishi Y; Ichiba ; Abe M; Isogai Y
Gan To Kagaku Ryoho; 1984 Sep; 11(9):1818-22. PubMed ID: 6476844
[TBL] [Abstract][Full Text] [Related]
4. [Effect of 7-N-(P-hydroxyphenyl)-mitomycin C (KW-2083) against pleuritis carcinomatosa].
Shimizu E; Saijo N; Shinkai T; Eguchi K; Tominaga K; Nomori H; Sasaki Y; Garcia-Herreros P; Hoshi A
Gan To Kagaku Ryoho; 1984 Jun; 11(6):1290-5. PubMed ID: 6732255
[TBL] [Abstract][Full Text] [Related]
5. [Anticancer activities of a new mitomycin derivative KW 2149, against human tumors xenografted into nude mice].
Nishiyama M; Kim R; Saeki T; Takagami S; Kirihara Y; Jinushi K; Toge T; Niimoto M; Hattori T
Gan To Kagaku Ryoho; 1988 Nov; 15(11):3133-7. PubMed ID: 3142368
[TBL] [Abstract][Full Text] [Related]
6. [Comparative study on the anticancer activities of KW2149 and mitomycin C against human tumor xenografts using subrenal capsule assay].
Takagami S; Nishiyama M; Kim R; Kirihara Y; Jinushi K; Saeki K; Saeki T; Nosoh Y; Niimoto M; Hattori T
Gan To Kagaku Ryoho; 1989 Jun; 16(6):2189-93. PubMed ID: 2500067
[TBL] [Abstract][Full Text] [Related]
7. [Phase II study of KW2083 [7-N-(p-hydroxyphenyl)-mitomycin C] in patients with carcinoma of the lung and metastatic pulmonary tumor].
Shinkai T; Saijo N; Tominaga K; Eguchi K; Shimizu E; Shibuya M; Shimabukuro Z
Gan To Kagaku Ryoho; 1983 Mar; 10(3):834-9. PubMed ID: 6882001
[TBL] [Abstract][Full Text] [Related]
8. [Phase I study of KW2083 7-N-(p-hydroxyphenyl) mitomycin C].
Gan To Kagaku Ryoho; 1982 Oct; 9(10):1844-50. PubMed ID: 7184379
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of 7-N-(p-hydroxyphenyl)-mitomycin C (KW2083) in patients with advanced non-small cell carcinoma of the lung and metastatic pulmonary tumors.
Shinkai T; Saijo N; Tominaga K; Eguchi K; Shimizu E; Sasaki Y; Fujita J; Futami H; Hoshi A
Jpn J Clin Oncol; 1985 Mar; 15(1):61-5. PubMed ID: 3981815
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetics of mitomycin C and its derivative (KW-2083)].
Fujita H
Gan To Kagaku Ryoho; 1982 Aug; 9(8):1362-73. PubMed ID: 6820913
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of the duocarmycin semisynthetic derivative KW-2189 given daily for five days every six weeks.
Alberts SR; Erlichman C; Reid JM; Sloan JA; Ames MM; Richardson RL; Goldberg RM
Clin Cancer Res; 1998 Sep; 4(9):2111-7. PubMed ID: 9748127
[TBL] [Abstract][Full Text] [Related]
12. [A phase II study of SM-5887 for advanced gastric cancer].
Tsushima K; Sakata Y; Munakata A; Sato T; Chiba Y; Nara H; Kawazu S; Matsukawa M; Ohmi T; Aizawa T
Gan To Kagaku Ryoho; 1991 Jun; 18(7):1151-4. PubMed ID: 1647150
[TBL] [Abstract][Full Text] [Related]
13. Nonenzymatic reductive activation of 7-N-((2-([2-(gamma-L-glutamylamino)ethyl]dithio)ethyl))mitomycin C by thiol molecules: a novel mitomycin C derivative effective on mitomycin C-resistant tumor cells.
Lee JH; Naito M; Tsuruo T
Cancer Res; 1994 May; 54(9):2398-403. PubMed ID: 8162587
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of 7-N-(p-hydroxyphenyl)-mitomycin C.
Meguro S; Nagata T; Yokoyama K; Chinen T; Yamazaki H; Kobayashi T; Isogai Y; Ogawa M
Invest New Drugs; 1984; 2(4):381-5. PubMed ID: 6511242
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity and toxicity in animals of BMY-25282, a new mitomycin derivative.
Bradner WT; Rose WC; Schurig JE; Florczyk AP; Huftalen JB; Catino JJ
Cancer Res; 1985 Dec; 45(12 Pt 1):6475-81. PubMed ID: 3933826
[TBL] [Abstract][Full Text] [Related]
16. [A phase I trial of 4'-epiadriamycin].
Ogawa M; Ikeda K; Inagaki J; Horikoshi N; Inoue K; Nakada K; Usui N; Okada Y; Adachi K; Tada A
Gan To Kagaku Ryoho; 1984 Apr; 11(4):926-9. PubMed ID: 6586111
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity and toxicity in animals of RR-150 (7-cysteaminomitosane), a new mitomycin derivative.
Bradner WT; Rose WC; Schurig JE; Schlein A; Huftalen JB
Cancer Res; 1984 Dec; 44(12 Pt 1):5619-23. PubMed ID: 6437670
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of mitomycin C in patients receiving the drug alone or in combination.
van Hazel GA; Scott M; Rubin J; Moertel CG; Eagan RT; O'Connell MJ; Kovach JS
Cancer Treat Rep; 1983 Sep; 67(9):805-10. PubMed ID: 6411337
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo.
Tsuruo T; Sudo Y; Asami N; Inaba M; Morimoto M
Cancer Chemother Pharmacol; 1990; 27(2):89-93. PubMed ID: 2123421
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of mitomycin C in humans.
den Hartigh J; McVie JG; van Oort WJ; Pinedo HM
Cancer Res; 1983 Oct; 43(10):5017-21. PubMed ID: 6411336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
